title: Growth Pattern in Paediatric Crohn Disease Is Related to Inflammatory Status.
abstract: The respective role of disease activity and steroid therapy in growth impairment in paediatric-onset Crohn disease (CD) is still debated. Our aim was to investigate whether the growth pattern of children with CD was correlated with the inflammatory status during the disease course, regardless the cumulative duration of steroid therapy.
  
  
  
  One hundred and seven patients with a diagnosis of CD <17 years, followed during ≥2 years and for whom ≥2 height measures were available during follow-up, were identified between 1998 and 2010. Height, C-reactive protein (CRP), orosomucoid, and steroid therapy duration were collected at each visit. The relationship between the evolution of growth velocity and inflammatory status during follow-up was investigated using a linear mixed model with random coefficients.
  
  
  
  Median age at diagnosis was 11.7 years (Q1-Q3: 9.8-13.5). Mean height for age (H/A) z score was 0.14 ± 1.29 at diagnosis and 0.05 ± 1.23 among the 75 patients who had reached their final height at maximal follow-up (median: 4.9 years; Q1-Q3: 3.8-6.4). Growth failure (H/A z score <-2) was present in 7 (8%) patients at diagnosis and 5 (5%) at maximal follow-up. Growth velocity was negatively correlated with the evolution of CRP (P < 0.0001) and orosomucoid (P < 0.0001) during follow-up. After adjustment for the cumulative duration of steroid therapy, these 2 correlations remained significant (CRP: P = 0.0008; orosomucoid: P < 0.0001).
  
  
  
  Children with CD with uncontrolled inflammatory status have a lower growth velocity. The inflammatory status should be kept as close to normal as possible in paediatric-onset patients with CD to optimize their growth pattern.
authors.affiliation: *Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Lille University Jeanne de Flandre Children's Hospital †Biostatistics Unit, Lille University Hospital, EA 2694 ‡Department of Public Health, Epidemiology and Economic Health, Epimad Registry, Lille University Hospital, University of Lille §Lille Inflammation Research International Centre LIRIC UMR 995, University of Lille, Inserm, CHU Lille, Lille, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Ley
authors.forename: Alain
authors.initials: A
authors.lastname: Duhamel
authors.forename: Hélène
authors.initials: H
authors.lastname: Behal
authors.forename: Francis
authors.initials: F
authors.lastname: Vasseur
authors.forename: Hélène
authors.initials: H
authors.lastname: Sarter
authors.forename: Laurent
authors.initials: L
authors.lastname: Michaud
authors.forename: Corinne
authors.initials: C
authors.lastname: Gower-Rousseau
authors.forename: Dominique
authors.initials: D
authors.lastname: Turck
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001827:Body Height; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D002657:Child Development; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006128:Growth; D006130:Growth Disorders / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009961:Orosomucoid / Q000032:analysis; D012042:Registries
chemical_list: D000893:Anti-Inflammatory Agents; D009961:Orosomucoid; D002097:C-Reactive Protein